On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details

Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Inks Major Contract; Skyline Medical Seals STREAMWAY Deal

POAI’s Soluble Biotech announces first substantial contract with pharmaceutical company since acquisition Founder calls contract “major milestone,” validation of move into new facility POAI’s Skyline Medical sells eight proprietary STREAMWAY(R) systems to Virginia-based hospital organization Soluble Biotech, a division of Predictive Oncology (NASDAQ: POAI), has finalized its first substantial contract with a pharmaceutical company since … Continue reading “Predictive Oncology Inc.’s (NASDAQ: POAI) Soluble Biotech Inks Major Contract; Skyline Medical Seals STREAMWAY Deal”

NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Granted License for Additional 71 Unique Ovarian Cancer Cell Lines

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, a division of the company, has received a license for an additional 71 unique ovarian cancer call lines. The licensing comes from England-based Ximbio, the largest nonprofit in the world dedicated to … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Granted License for Additional 71 Unique Ovarian Cancer Cell Lines”

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary’s CIO Discusses Curing Cancer with AI on DojoLIVE! Interview

POAI subsidiary Helomics exec discusses the company’s quest to fight cancer Helomics tapping into the fast growing, billion-dollar AI in drug discovery market Pittsburgh-based company has been building foundational groundwork in cancer drug response profiling for two decades Helomics harnesses rich historic tumor data with the power of AI to test living tumor tissues Predictive … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary’s CIO Discusses Curing Cancer with AI on DojoLIVE! Interview”

NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Helomics Provide Key Insight to Personalized Cancer Treatment

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, lives by the motto: Cancer is personal; we believe therapy should be too. The company’s subsidiary Helomics builds AI-driven models designed to predict drug response and patient outcome of individual tumors. The company is able to do that because it … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Helomics Provide Key Insight to Personalized Cancer Treatment”

Predictive Oncology Inc. (NASDAQ: POAI) Confirms Attendance at Upcoming LD 500 Microcap Investor Conference

Predictive Oncology presenting at upcoming LD 500 investor conference Investor event will take place Sept. 1-4, 2020 and will feature 500 handpicked companies from across North American listed micro-cap universe Predictive Oncology specializes in applying data and artificial intelligence to cancer personalized medicine, drug discovery Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Confirms Attendance at Upcoming LD 500 Microcap Investor Conference”

NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Recent Board Appointments Combine Deep Experience, Expertise to Drive Strategic Vision

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, recently announced board appointments to align expertise with the company’s strategic vision. These recently appointed board members — Dr. Nancy Chung-Welch, PhD; Charles L. Nuzum, CPA; and Greg St. Clair — bring to POAI more than a century of … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Recent Board Appointments Combine Deep Experience, Expertise to Drive Strategic Vision”

Predictive Oncology Inc. (NASDAQ: POAI) Starts Presentation at The LD 500

Predictive Oncology Inc. (NASDAQ: POAI) operates through three segments (domestic, international and other), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Starts Presentation at The LD 500”

NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Slated for Presentation at Prestigious LD 500 Virtual Investor Conference

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that company executives will be presenting at LD Micro’s elite LD 500 Virtual Investor Conference. The presentation is scheduled for Wednesday, Sept. 2, 2020, at 3:40 p.m. ET. An archived copy of the webcast … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Slated for Presentation at Prestigious LD 500 Virtual Investor Conference”

NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) and TumorGenesis Advancing Path Toward Patient-Specific Treatments

Predictive Oncology (NASDAQ: POAI), together with its TumorGenesis subsidiary, has achieved significant breakthroughs in applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Earlier in June, TumorGenesis, which is developing a new rapid approach to growing tumors in the laboratory, sold its first order of unique ovarian cancer cell culture media to … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) and TumorGenesis Advancing Path Toward Patient-Specific Treatments”

Predictive Oncology Inc.’s (NASDAQ: POAI) Exclusive Resources Provide Personal Profiling, Tools to Improve Patient Outcomes

POAI, Helomics builds AI-driven models that predict drug response, patient outcome Company tests patient tumor, generates comprehensive picture that oncologists use to individualize therapy Key to individualized insight is POAI’s Tumor Drug Response Profiling (“TDRP”) platform, NGS-based genomic profiling, unmatched cancer knowledge base Guided by the mantra that “cancer is personal — we believe therapy … Continue reading “Predictive Oncology Inc.’s (NASDAQ: POAI) Exclusive Resources Provide Personal Profiling, Tools to Improve Patient Outcomes”

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217